KR20040023755A - New use of some lactobacillus strains in treating allergy - Google Patents

Abstract

PURPOSE: The use of lactobacillus strains stimulating INF-gamma secretion as a therapeutic agent for the treatment of allergy is provided. The therapeutic agent contains the lactic acid bacterial strain and is effective in treating allergy without causing adverse side effects. CONSTITUTION: To treat allergy in a subject, a composition containing a lactic acid bacterial strain stimulating INF-gamma secretion is administered to the subject. The strain is selected from the group consisting of Lactobacillus plantarum CCRC 12944, Lactobacillus acidophilus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei subsp. paracasei CCRC 14023, Lactobacillus delbrueckii subsp. bulgaricus CCRC 12297, Lactobacillus delbrueckii subsp. bulgaricus CCRC 14007, and Lactobacillus delbrueckii subsp. bulgaricus CCRC 14069.

Description

New use of some lactobacillus strains in treating allergy

The present invention relates primarily to new uses of some Lactobacillus strains in the treatment of allergies.

Allergy generally refers to the acquired potential to cause immunologically mediated side effects on harmless substances. Allergic reactions cause symptoms such as itching, coughing, wheezing, sneezing, tearing, inflammation and fatigue. Allergic reactions are commonly believed to include an early specific immune response and a late inflammatory reaction. Allergens (eg pollen and tick dust) have been reported to mediate the early stages of allergy by stimulating high affinity immunoglobulin (IgE) receptors. For example, mast cells and basophils secrete histamine and cytokines when stimulated by allergens. The cytokines secreted from mast cells and basophils then mediate the late stages of allergy by recruiting inflammatory cells. In addition, eosinophils, macrophages, lymphocytes, neutrophils and platelets have been reported to initiate a fierce inflammatory cycle. This late stage of allergy amplifies the initial immune response, which triggers the release of more inflammatory cells (Blease et al., Chemokines and their role in airway hyper-reactivity. Respir Res 2000; 1: 54-61).

Various therapies have been studied to treat the symptoms of allergies. Among them, anti-allergic agents and histamine H-receptor antagonists (anti-histamines) are used. Histamine antagonists are administered to neutralize the activity of histamine secreted from mast cells in response to the presence of allergens. They function to reduce redness, itching and swelling caused by the action of histamine on target tissues, and to prevent or alleviate many of the symptoms resulting from degranulation of mast cells. However, anti-histamines are also associated with side effects such as decreased alertness, slow reaction time and somnolence (US Pat. No. 6,225,332).

There are also some reports on the treatment of allergies by modulating cytokines. Among them, interferon- [gamma] (INF- [gamma]) is known to inhibit over-expression of cytokines in Th2 lymphocytes, and in particular to inhibit the proliferation of B cells by inhibiting the secretion of IL-4. In addition, INF-γ may promote Th1 immune response and inhibit IgE synthesis (Sareneva T et al., Influenza A virus-induced INF-α / β and IL-18 synergistically enhance INF-γ gene expression in human T cells.J Immunol 1998; 160: 6032-6038; Shida K et al., Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte culture.Int Arch Allergy Immunol 1998; 115: 278-287). Since INF-γ can inhibit B cell proliferation and IgE secretion, it is believed that INF-γ is effective for treating allergy.

Lactic acid bacteria, which are Gram-positive bacteria, are generally used for industrial food fermentation. In recent studies, lactic acid bacteria have been reported to promote INF-γ secretion of cells (Contractor NV et al., Lymphoid hyperplasia, autoimmunity and compromised intestinal intraepithelial lymphocyte development in colits-free gnotobiotic IL-2-deficient mice.J Immunol 1998; 160: 385-394). Some specific lactic acid bacteria, such as Bifidobacterium lactis and Lactobacillus brevis subsp., Are known to promote INF-γ secretion of lymphocytes in blood derived from mice and humans (US Patent publication US 2002/0031503 A1; US Pat. No. 5,556,785). Lactic acid bacteria also stimulate lymphocytes derived from humans or mice to secrete interleukin-12 (IL-12), a T cell stimulating cytokine that activates T cells and NK cells to secrete INF-γ. (Hessle et al., Lactobacilli from human gastrointestinal mucosa are strong stimulatiors of IL-12 production. Clin Exp Immunol 1999; 116: 276-282).

Therefore, the present invention has a technical problem to provide a method and composition for treating allergy without side effects using a lactic acid bacterial strain that promotes INF-γ secretion.

1 depicts INF-γ secretion in coculture of Lactobacillus strains and lymphocytes. The secretion of INF-γ was detected by ELISA after co-culture of lactic acid bacteria and lymphocytes for 12 and 36 hours. The content of INF-γ is expressed as absorbance (OD value). In the figure, "PC" indicates Lactobacillus casei CCRC 10697 as a positive control; "NC" denotes a Lactobacillus del Brewer subspecies station Bulgaria kusu CCRC 14071 (Lactobacillus delbrueckii subsp bulgaricus CCRC 14071.) As a negative control; 1 represents Lactobacillus plantarum CCRC 12944; 2 represents Lactobacillus acidophilus CCRC 14079; 3 represents Lactobacillus rhamnosus CCRC 10940; 4 is a Lactobacillus spp para para Kasei Kasei CCRC 14023 (. Lactobacillus paracasei subsp paracasei CCRC 14023) represents; 5 represents Lactobacillus delbrueckii subsp.bulgaricus CCRC 12297; 6 represents Lactobacillus delbrueckii subsp.bulgaricus CCRC 14007; 7 shows a Lactobacillus del Brewer subspecies station Bulgaria kusu CCRC 14069 (Lactobacillus delbrueckii subsp. Bulgaricus CCRC 14069).

2 shows the secretion of INF-γ in co-cultures of Lactobacillus strains and peripheral blood mononuclear cells (PBMCs). The secretion of INF-γ was detected by ELISA after co-culture of lactic acid bacteria and PBMCs for 12 hours, 48 hours and 72 hours. The content of INF-γ is expressed by absorbance (O.D. value). During the test, Lactobacillus casei CCRC 10697 served as a positive control; Lactobacillus delbrueki subspecies Bulgaricus CCRC 14071 was used as a negative control; Lactobacillus paracasei subspecies Paracasei CCRC 14023 was tested.

The present invention provides new uses of some Lactobacillus strains.

An object of the present invention is a method for treating allergy in a subject, comprising administering to the subject an agent comprising a lactic acid bacterial strain that promotes INF-γ secretion, the strain is Lactobacillus planta Rooms CCRC 12944, Lactobacillus asidophilus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracassei subspecies Paracasei CCRC 14023, Lactobacillus delbrueki subspecies Bulgaricus CCRC 12297, Lactobacillus delbrueki subspecies Bulgari CCRC 14007 and Lactobacillus delbrueki subspecies Bulgaricus CCRC 14069.

In another aspect, the present invention is a composition for treating allergy, comprising a therapeutically effective amount of lactic acid bacteria strains promoting INF-γ secretion to treat allergy, the strain is Lactobacillus plantarum CCRC 12944, Lactobacillus asidophilus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei subspecies Paracasei CCRC 14023, Lactobacillus delbrueki subspecies Bulgaricus CCRC 12297, Lactobacillus delbruechi subspecies Bulgari CCRC 14007 and It provides a composition, characterized in that selected from the group consisting of Lactobacillus delbrueckia subspecies Bulgaricus CCRC 14069.

According to the present invention, some Lactobacillus strains that promote INF- [gamma] secretion have been unexpectedly discovered and can be used to treat allergies.

In one aspect, the invention provides a method for treating allergy in a subject, comprising administering to the subject an agent comprising a strain of lactic acid bacteria that promotes INF-γ secretion, the strain being Lactobacillus Planta Room CCRC 12944, Lactobacillus asidophilus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei spp. CUCUS CCRC 14007 and Lactobacillus delbrueckia subspecies Bulgaricus CCRC 14069 provide a therapeutic method, wherein all strains are selected from the Food Industry Research and Development Institute (FIRDI), Hsinchu, Taiwan). The above mentioned strains are publicly available from FIRDI. They meet the Standards, which are considered safe, natural, non-toxic and generally safe (G.R.A.S.). Strains are commonly used in foods and are harmless to the human body.

According to the invention, the strains have been demonstrated to have the ability to promote INF-γ secretion when co-cultured with lymphocytes. One of these strains has been demonstrated to promote INF-γ secretion of peripheral blood mononuclear cells (PBMCs). In the most preferred embodiment of the invention, the Lactobacillus paracasei subspecies Paracasei CCRC 14023 has been demonstrated to have a better ability (4 fold) in promoting INF-γ secretion than the Lactobacillus casei CCRC 10697 as a positive control.

According to the present invention, the lactic acid bacterial strains used for the treatment of allergy may be live or inactivated. For example, live bacterial strains can be treated by heating methods or by various methods commonly used in the art to kill lactic acid bacterial strains to obtain inactivated strains.

As used herein, the term "allergy" refers to an INF-γ mediated allergy. Allergic diseases include rhinitis, sinusitis, asthma, irritable pneumonia, extrinsic allergic alveolitis, conjunctivitis, urticaria, eczema, dermatitis, anaphylaxis, angioedema, allergic And migraine headaches, and certain digestive disorders. Atopic eczema has proved treatable with probiotics that promote INF-γ secretion (Isolauri E et al., Probiotics in the management of atpic eczema. Clinical and experimental Allergy 2000; 30: 1604-1610; Sutas Y et al., Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus caseiGG-derived enzyme J Allergy Clin Immunol 1996; 98:.. 216-224; Kalliomaki etc., Probiotics in primary prevention of atopic disease : a randomized placebo-controlled trial Lancet 2001; 357: 1076-79).

In another aspect, the invention is a composition for treating allergy, comprising a therapeutically effective amount of a lactic acid bacterial strain that promotes INF-γ secretion to treat allergy, the strain is Lactobacillus plantarum CCRC 12944, Lactobacillus asidophilus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei subspecies Paracasei CCRC 14023, Lactobacillus delbrueki subspecies Bulgaricus CCRC 12297, Lactobacillus delbruechi subspecies Bulgari CCRC 14007 and It provides a composition, characterized in that selected from the group consisting of Lactobacillus delbrueckia subspecies Bulgaricus CCRC 14069.

According to the present invention, lactic acid bacterial strains may be included in pharmaceutical compositions, dietary supplements, foods or components thereof generally ingested by humans. In a preferred embodiment of the present invention, the lactic acid bacterial strain can be delivered in the form of a food such as coagulated dairy product prepared through lactic acid fermentation in milk. Food prepared according to the present invention may be conveniently administered to infants or children.

The following examples are merely to illustrate the invention, but not to limit the scope of the invention.

Example 1 Screening of Lactic Acid Bacterial Strains Promoting INF-γ Secretion in Lymphocytes

Bacterial Culture : The 67 lactic acid bacterial strains listed in Table 1 were preselected. Strains as positive control (PC) and negative control (NC) are also described. All strains were obtained from FIRDI.

number Lactic Acid Bacteria CCRC number PC Lactobacillus casei 10697 NC Lactobacillus delbrueckii subsp. bulgaricus 14071 One Lactobacillus plantarum 10069 2 Lactobacillus plantarum 10357 3 Lactobacillus plantarum 11697 4 Lactobacillus plantarum 12250 5 Lactobacillus plantarum 12251 6 Lactobacillus plantarum 12327 7 Lactobacillus plantarum 12944 8 Lactobacillus plantarum 14059 9 Lactobacillus plantarum 15478 10 Lactobacillus johnsonii 14004 11 Lactobacillus acidophilus 14026 12 Lactobacillus rhamnosus 14029 13 Lactobacillus acidophilus 14064 14 Lactobacillus acidophilus 14065 15 Lactobacillus acidophilus 14079 16 Lactobacillus sp. 16000 17 Lactobacillus acidophilus 16092 18 Lactobacillus acidophilus 16099 19 Lactobacillus acidophilus 17009 20 Lactobacillus acidophilus 17064 21 Lactobacillus acidophilus 10695 22 Lactobacillus casei subsp . casei 10358 23 Lactobacillus rhamnosus 10940 24 Lactobacillus casei subsp . casei 11197 25 Lactobacillus rhamnosus 11673 26 Lactobacillus paracasei subsp . paracasei 12193 27 Lactobacillus paracasei subsp . paracasei 12248 28 Lactobacillus casei subsp . casei 12249 29 Lactobacillus casei subsp . casei 12272 30 Lactobacillus paracasei subsp . paracasei 14001 31 Lactobacillus paracasei subsp . paracasei 14023 32 Lactobacillus casei subsp . casei 14025 33 Lactobacillus casei subsp . casei 14073 34 Lactobacillus casei subsp . casei 14074 35 Lactobacillus casei subsp . casei 14080 36 Lactobacillus casei subsp . casei 14082 37 Lactobacillus casei subsp . casei 14083 38 Lactobacillus casei subsp . casei 14084 39 Lactobacillus casei subsp . casei 14705 40 Lactobacillus casei subsp . casei 16093

41 Lactobacillus casei subsp. casei 16094 42 Lactobacillus paracasei subsp. paracasei 16100 43 Lactobacillus casei subsp. casei 17001 44 Lactobacillus casei subsp. casei 17002 45 Lactobacillus casei subsp. casei 17004 46 Lactobacillus casei subsp. casei 17005 47 Lactobacillus delbruekii subsp. bulagricus 10696 48 Lactobacillus helveticus 11052 49 Lactobacillus delbruekii subsp. bulagricus 12255 50 Lactobacillus delbruekii subsp. bulagricus 12297 51 Lactobacillus delbruekii subsp. bulagricus 14007 52 Lactobacillus delbruekii subsp. bulagricus 14008 53 Lactobacillus delbruekii subsp. bulagricus 14009 54 Lactobacillus delbruekii subsp. bulagricus 14010 55 Lactobacillus delbruekii subsp. bulagricus 14069 56 Lactobacillus delbruekii subsp. bulagricus 14075 57 Lactobacillus delbruekii subsp. bulagricus 14077 58 Lactobacillus delbruekii subsp. bulagricus 14090 59 Lactobacillus delbruekii subsp. bulagricus 14091 60 Lactobacillus delbruekii subsp. bulagricus 14098 61 Lactobacillus delbruekii subsp. bulagricus 16050 62 Lactobacillus delbruekii subsp. bulagricus 16051 63 Lactobacillus delbruekii subsp. bulagricus 16052 64 Lactobacillus delbruekii subsp. bulagricus 16053 65 Lactobacillus paracasei subsp. paracasei 12188 66 Lactobacillus brevis 12247 67 Lactobacillus brevis 14060

Among them, 38 strains met the standard which was considered safe, natural, non-toxic and generally safe (General Regarded as Safe, G.R.A.S.). All strains were incubated in a Lactobacillus MRS liquid medium (DIFCO 0881) at 37 ° C. until stationary phase, collected by centrifugation at 3000 g for 15 minutes, and collected in 2 mL and 1 mL PBS (phosphate buffered saline, pH 7.2). Cultures of the strains were resuspended in 1 mL PBS, heated at 95 ° C. for 30 minutes, then autoclave and stored in PBS at −20 ° C.

Lymphocyte culture : HL-60 CCRC 60273 (clone 15 HL-60) cells (purchased from FIRDI) were treated according to the method described by Fishkov (Fischkoff SA Gradedincrease in probability of eosinophilic differentiation of HL-60 promyelocytic leukemia cells induced by culture under alkaline condition.Leukemia Research 1988; 12 (8): 679-686). HL-60 cells were subcultured in RPMI 1640 (pH 7.2), induced to differentiate into eosinophils, and then passaged to RPMI 1640 (pH 7.7) for generations to obtain lymphocyte samples. In each lymphocyte sample, the cell density was adjusted to be 5 x 10 ⁶ cells per sample. Lymphocyte samples were incubated for 6 hours in 2 mL RPMI 1640, pH 7.7.

Promoting INF- [gamma] secretion: Lymphocyte samples were co-cultured with a predetermined amount of the above mentioned bacterial strains. Lactobacillus casei CCRC 10697 was used as a positive control, and Lactobacillus delbrueki subspecies Bulgaricus CCRC 14071 was used as a negative control. After 12, 36 and 60 hours of co-culture, cells in each sample were collected respectively. The collected cells were resuspended and centrifuged for 5 minutes at 2000 rpm. Supernatants were taken to determine the level of INF-γ in each sample.

Measurement of INF-γ levels: Methods for measuring INF-γ levels by ELISA are described by Shida et al. (Shida K., Makino K., Morishita A., Takamizawa K., Hachimura S., Ametani A. , Takehito S., Kumagai Y., Habu S., Kaminogawa S. Lactobacillus casei inhibits antigen induced IgE secretion through regulation of cytokine production in murine splenocyte cultures.Int Arch Allergy Immunol 1998; 115: 278-287). Contains:

At 2.5 μg / mL in coating buffer (8.00 g NaCl, 0.20 g KCl, 1.44 g Na ₂ HPO ₄ , 0.24 g KH ₂ PO ₄ , 30.0 g bovine serum albumin, and 0.50 g NaN ₃ per liter, pH 7.4) Adding 150 [mu] l of purified mouse anti-human INF- [gamma] antibody into each well in an ELISA plate;

Shaking the plate at 40 rpm at room temperature;

Removing the coating buffer in the wells;

In wash buffer (8.00 g NaCl, 0.20 g KCl, 1.44 g Na ₂ HPO ₄ , 0.24 g KH ₂ PO ₄ , 0.5 mL Tween 20, and 0.50 g NaN ₃ per liter, pH 7.4) twice Washing each well of the plate over;

Washing the wells with distilled water;

Adding 200 μl of block buffer into each well of the plate;

Incubating the plate for at least 2 hours at room temperature;

Removing the block buffer in the wells;

Washing each well of the plate three times for three minutes with wash buffer;

Washing each well of the plate with distilled water;

Taking the supernatant of the lymphocyte sample and adding it to each well of the plate;

Rocking the plate overnight at 4 ° C. at 40 rpm;

Removing the sample in the well;

Washing each well of the plate three times for three minutes with washing buffer and then washing with distilled water;

Adding 150 μl of biotin mouse anti-human INF-γ antibody diluted in dilution buffer into each well of the plate;

Incubating the plate for 2 hours at room temperature;

Washing each well of the plate three times for three minutes with washing buffer and then washing with distilled water;

Adding 150 μl of streptavidin-alkaline phosphatase (Streptavidine-AKP) diluted with dilution buffer into each well of the plate;

Incubating the plate for 1 hour at room temperature;

Washing each well of the plate four times with washing buffer for three minutes, followed by washing with distilled water;

Adding 150 μl of substrate, p-nitrophenyl phosphate (pNpp) into each well of the plate;

Incubating the plate at room temperature until the substrate reaction is complete;

Measuring the absorbance of each well of the plate at 405 nm (ie OD405).

Results: The results of INF-γ levels promoted by 67 lactic acid bacterial strains are listed in Table 2.

CCRC number 12 hours (OD) 36 hours (OD) 60 hours (OD) Positive control 0.156 0.295 0.106 Negative control 0.117 0.241 0.103 10069 0.117 0.304 0.107 10357 0.129 0.267 0.104 11697 0.112 0.397 0.104 12250 0.122 0.335 0.156 12251 0.177 0.293 0.110 12327 0.131 0.289 0.111 12944 0.152 0.427 0.092 14059 0.111 0.363 0.102 15478 0.157 0.385 0.109 14004 0.162 0.399 0.106 14026 0.115 0.405 0.103 14029 0.131 0.272 0.110 14064 0.114 0.337 0.164 14065 0.159 0.244 0.110 14079 0.142 0.342 0.099 16000 0.123 0.255 0.105 16092 0.127 0.254 0.114 16099 0.114 0.262 0.114 17009 0.111 0.276 0.117 17064 0.147 0.272 0.114 10695 0.131 0.274 0.118 10358 0.148 0.271 0.119 10697 0.160 0.340 0.098 10940 0.336 0.335 0.109 11197 0.150 0.293 0.104 11673 0.109 0.298 0.106 12193 0.116 0.305 0.111 12248 0.160 0.284 0.112 12249 0.142 0.267 0.112 12272 0.120 0.276 0.112 14001 0.173 0.410 0.108 14023 0.120 0.538 0.125 14025 0.142 0.339 0.110 14073 0.157 0.398 0.104 14074 0.125 0.455 0.117 14080 0.124 0.308 0.116 14082 0.148 0.248 0.113 14083 0.129 0.203 0.116 14084 0.153 0.335 0.121

14705 0.159 0.277 0.122 16093 0.131 0.328 0.127 16094 0.160 0.309 0.114 16100 0.158 0.316 0.121 17001 0.219 0.252 0.123 17002 0.155 0.207 0.120 17004 0.236 0.112 0.119 17005 0.125 0.320 0.104 10696 0.122 0.373 0.122 11052 0.142 0.316 0.107 12255 0.118 0.325 0.116 12297 0.121 0.418 0.105 14007 0.122 0.502 0.110 14008 - 0.359 0.100 14009 0.224 0.293 0.103 14010 0.150 0.312 0.100 14069 0.146 0.440 0.161 14071 0.144 0.270 0.099 14075 0.152 0.319 0.100 14077 0.163 0.342 0.102 14090 0.203 0.302 0.106 14091 0.184 0.288 0.097 14098 0.147 0.242 0.101 16050 0.136 0.264 0.098 16051 0.135 0.250 0.103 16052 0.132 0.386 0.104 16053 0.132 0.314 0.113 12188 0.150 0.263 0.101 12247 0.137 0.246 0.103 14060 0.167 0.328 0.103

Of the 67 strains, the following seven strains were found to be capable of promoting INF-γ secretion in lymphocyte cells: Lactobacillus plantarum CCRC 12944, Lactobacillus asidophilus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei subspecies Paracasei CCRC 14023, Lactobacillus delbrueki subspecies Bulgaricus CCRC 12297, CCRC 14007 and CCRC 14069. The results are shown in FIG. The OD405 levels of Lactobacillus paracasei subspecies ParaCase CCRC 14023 and Lactobacillus delbrueki subspecies Bulgaricus CCRC 12297, CCRC 14007 and CCRC 14069 were higher than the positive control and even four times higher than the negative control. In addition, except for Lactobacillus rhamnosus (CCRC 10940), the OD405 levels of the strains collected after 36 hours of coculture were three times higher than those collected after 12 hours of coculture.

Example 2: INF-γ Secretion in Peripheral Blood Mononuclear Cells by Stimulation of Lactic Acid Bacteria

Separation of Peripheral Blood Mononuclear Cells: 5 mL Ficoll-Hypaque (17-1400-02, Pharmacia) was added to 5 mL blood samples from healthy volunteers and centrifuged at 500 g for 30 minutes. Peripheral blood mononuclear cells (PBMCs) were taken from the interface of the samples and washed twice with PBS. PBMCs (105 cells / mL) were transferred to wells of 6-well plates, each well containing 2 mL RPMI 1640 medium at pH 7.7.

Promoting INF-γ Secretion: Using similar methods as described in Example 1, PBMCs were prepared using Lactobacillus plantarum CCRC 12944, Lactobacillus asydophylus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei Coculture with Subspecies Paracasei CCRC 14023, Lactobacillus delbrueki subspecies Bulgaricus CCRC 12297, Lactobacillus delbrueki subspecies Bulgaricus CCRC 14007 and Lactobacillus delbrueki subspecies Bulgaricus CCRC 14069 (10 ⁷ cells / mL) It was. Lactobacillus casei CCRC 10697 was taken as a positive control, and Lactobacillus delbrueki subspecies Bulgaricus CCRC 14071 was taken as a negative control. Cells were collected after 24, 48, 72 hours co-culture, resuspended and centrifuged for 5 minutes at 2000 rpm. Supernatant was taken to determine the INF-γ level in the same manner as described in Example 1.

Results: The results of INF-γ content of PBMCs promoted by seven strains are listed in Table 3, and in particular, the results by Lactobacillus paracasei subspecies paracasei CCRC 14023 are shown in FIG. 2.

time CCRC number OD INF-γ concentration (ng / ml) 24 hours Positive control 0.1945 861.5 12944 0.1685 731.5 14079 0.1895 836.5 10940 0.223 1004 14023 0.23 1039 12297 0.195 864 14007 0.165 714 14069 0.2015 896.5 48 hours Positive control 0.2095 936.5 12944 0.1605 691.5 14079 0.244 1109 10940 0.305 1414 14023 0.267 1224 12297 0.1555 666.5 14007 0.141 594 14069 0.165 714 72 hours Positive control 0.2575 1176.5 12944 0.159 684 14079 0.17 739 10940 0.193 854 14023 0.1895 836.5 12297 0.147 624 14007 0.133 554 14069 0.17 739

OD405 levels of samples collected after 24 hours co-culture were 1.2 times higher than negative controls; Collection after 48 hours co-culture was 1.8 times higher than negative control and 1.3 times higher than positive control; The collection after 72 hours co-culture was 1.3 times higher than the negative control.

Although embodiments of the present invention have been described and described, various modifications and improvements may be made by those skilled in the art. The present invention is not limited to the specific forms described, and all modifications without departing from the spirit and scope of the invention fall within the scope of the invention as defined by the appended claims.

The present invention can provide methods and compositions for treating allergies using some lactic acid bacterial strains that promote INF-γ secretion.

Claims (21)

A method for treating allergy in a subject, comprising administering to the subject an agent comprising a strain of lactic acid bacteria that promotes INF-γ secretion, the strain being Lactobacillus plantarum CCRC 12944, Lactobacillus Ashdophylus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei subspecies Paracasei CCRC 14023, Lactobacillus del breweries Subspecies Bulgari CCRC 12297, Lactobacillus del breweries subspecies Bulgari CCRC 14007 and Lactobacillus del brew E. coli Bulgaricus CCRC 14069 Allergy treatment method characterized in that selected from the group consisting of. The method of claim 1, wherein the lactic acid bacterial strain is Lactobacillus plantarum CCRC 12944. The method of claim 1, wherein the lactic acid bacterial strain is Lactobacillus asidophilus CCRC 14079. The method of claim 1, wherein the lactic acid bacterial strain is Lactobacillus rhamnosus CCRC 10940. The method of claim 1, wherein the lactic acid bacterial strain is Lactobacillus paracasei subspecies Paracasei CCRC 14023. The method of claim 1, wherein the lactic acid bacterial strain is Lactobacillus delbrueckia subtype Bulgaricus CCRC 12297. The method of claim 1, wherein the lactic acid bacterial strain is Lactobacillus delbrueckia subtype Bulgaricus CCRC 14007. The method of claim 1, wherein the lactic acid bacterial strain is Lactobacillus delbrueckia subtype Bulgaricus CCRC 14069. The method of claim 1, wherein the lactic acid bacterial strain is alive or inactivated. 10. The method of claim 9, wherein the lactic acid bacterial strain is inactivated. A composition for treating allergy, comprising a therapeutically effective amount of a lactic acid bacterial strain that promotes INF-γ secretion to treat allergy, the strain comprising Lactobacillus plantarum CCRC 12944, Lactobacillus asidophyllus. CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei subspecies Paracasei CCRC 14023, Lactobacillus del breweries subspecies Bulgaricus CCRC 12297, Lactobacillus del brewes subspecies Bulgaricus CCRC 14007 and Lactobacillus del brewes subspecies Bulgari A composition characterized in that it is selected from the group consisting of CCRC 14069. The composition of claim 11, wherein the lactic acid bacterial strain is Lactobacillus plantarum CCRC 12944. 12. The composition of claim 11, wherein the lactic acid bacterial strain is Lactobacillus asidophilus CCRC 14079. The composition of claim 11, wherein the lactic acid bacterial strain is Lactobacillus rhamnosus CCRC 10940. 12. The composition of claim 11, wherein the lactic acid bacterial strain is Lactobacillus paracasei subspecies paracasei CCRC 14023. 12. The composition of claim 11, wherein the lactic acid bacterial strain is Lactobacillus delbrueckia subtype Bulgaricus CCRC 12297. 12. The composition of claim 11, wherein the lactic acid bacterial strain is Lactobacillus delbrueki subtype Bulgaricus CCRC 14007. 12. The composition of claim 11, wherein the lactic acid bacterial strain is Lactobacillus delbrueckia subtype Bulgaricus CCRC 14069. 12. The composition of claim 11, wherein said lactic acid bacterial strain is live or inactivated. 20. The composition of claim 19, wherein said lactic acid bacterial strain is inactivated. 12. The composition of claim 11, wherein said composition is in the form of a pharmaceutical composition, dietary supplement, food or ingredient thereof.